1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 72, 2021
  5. Article

Annual Review of Medicine

Volume 72, 2021

Advances in Human Lung Transplantation

Abstract

Lung transplantation improves survival and quality of life in patients with advanced pulmonary disease. Over the past several decades, the volume of lung transplants has grown substantially, with increasing transplantation of older and acutely ill individuals facilitated by improved utilization and preservation of available donor organs. Other advances include improvements in the diagnosis and mechanistic understanding of frequent post-transplant complications, such as primary graft dysfunction, acute rejection, and chronic lung allograft dysfunction (CLAD). CLAD occurs as a result of the host immune response to the allograft and is the principal factor limiting long-term survival after lung transplantation. Two distinct clinical phenotypes of CLAD have emerged, bronchiolitis obliterans syndrome and restrictive allograft syndrome, and this distinction has enabled further understanding of underlying immune mechanisms. Building on these advances, ongoing studies are exploring novel approaches to diagnose, prevent, and treat CLAD. Such studies are necessary to improve long-term outcomes for lung transplant recipients.

Keyword(s): bronchiolitis obliterans, graft rejection, lung transplantation, organ preservation, primary graft dysfunction
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-080119-103200
2021-01-27
2024-04-26
Loading full text...

Full text loading...

/deliver/fulltext/med/72/1/annurev-med-080119-103200.html?itemId=/content/journals/10.1146/annurev-med-080119-103200&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Chambers DC, Cherikh WS, Harhay MO et al. 2019. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation report—2019; focus theme: donor and recipient size match. J. Heart Lung Transplant. 38:1042–55
     [Google Scholar]
  2. 2. 
    Valapour M, Lehr CJ, Skeans MA et al. 2020. OPTN/SRTR 2018 annual data report: lung. Am. J. Transplant. 20:427–508
     [Google Scholar]
  3. 3. 
    Weill D, Benden C, Corris PA et al. 2015. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 34:1–15
     [Google Scholar]
  4. 4. 
    Hayanga JWA, Hayanga HK, Holmes SD et al. 2019. Mechanical ventilation and extracorporeal membrane oxygenation as a bridge to lung transplantation: closing the gap. J. Heart Lung Transplant. 38:1104–11
     [Google Scholar]
  5. 5. 
    Hayes D Jr, Tobias JD, Tumin D. 2016. Center volume and extracorporeal membrane oxygenation support at lung transplantation in the lung allocation score era. Am. J. Respir. Crit. Care Med. 194:317–26
     [Google Scholar]
  6. 6. 
    Hayes D Jr, Whitson BA, Black SM et al. 2015. Influence of age on survival in adult patients on extracorporeal membrane oxygenation before lung transplantation. J. Heart Lung Transplant. 34:832–38
     [Google Scholar]
  7. 7. 
    Biswas Roy S, Alarcon D, Walia R et al. 2015. Is there an age limit to lung transplantation. Ann. Thorac. Surg. 100:443–51
     [Google Scholar]
  8. 8. 
    Lehr CJ, Blackstone EH, McCurry KR et al. 2020. Extremes of age decrease survival in adults after lung transplant. Chest 157:907–15
     [Google Scholar]
  9. 9. 
    Schaffer JM, Singh SK, Reitz BA et al. 2015. Single versus double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA 313:936–48
     [Google Scholar]
  10. 10. 
    Thabut G, Christie JD, Ravaud P et al. 2008. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet 371:744–51
     [Google Scholar]
  11. 11. 
    Anderson MR, Tabah A, RoyChoudhury A, Lederer DJ 2019. Procedure preference and intention-to-treat outcomes after listing for lung transplantation among U.S. adults. A cohort study. Ann. Am. Thorac. Soc. 16:231–39
     [Google Scholar]
  12. 12. 
    Nakajima D, Cypel M, Bonato R et al. 2016. Ex vivo perfusion treatment of infection in human donor lungs. Am. J. Transplant. 16:1229–37
     [Google Scholar]
  13. 13. 
    Nakajima D, Liu M, Ohsumi A et al. 2017. Lung lavage and surfactant replacement during ex vivo lung perfusion for treatment of gastric acid aspiration-induced donor lung injury. J. Heart Lung Transplant. 36:577–85
     [Google Scholar]
  14. 14. 
    Loor G, Warnecke G, Villavicencio MA et al. 2019. Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial. Lancet Respir. Med. 7:975–84
     [Google Scholar]
  15. 15. 
    Machuca TN, Cypel M, Bonato R et al. 2017. Safety and efficacy of ex vivo donor lung adenoviral IL-10 gene therapy in a large animal lung transplant survival model. Hum. Gene Ther. 28:757–65
     [Google Scholar]
  16. 16. 
    Hall DJ, Jeng EI, Gregg JA et al. 2019. The impact of donor and recipient age: older lung transplant recipients do not require younger lungs. Ann. Thorac. Surg. 107:868–76
     [Google Scholar]
  17. 17. 
    Diamond JM, Lee JC, Kawut SM et al. 2013. Clinical risk factors for primary graft dysfunction after lung transplantation. Am. J. Respir. Crit. Care Med. 187:527–34
     [Google Scholar]
  18. 18. 
    Bonser RS, Taylor R, Collett D et al. 2012. Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry. Lancet 380:747–55
     [Google Scholar]
  19. 19. 
    Woolley AE, Singh SK, Goldberg HJ et al. 2019. Heart and lung transplants from HCV-infected donors to uninfected recipients. N. Engl. J. Med. 380:1606–17
     [Google Scholar]
  20. 20. 
    Snell GI, Yusen RD, Weill D et al. 2017. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: definition and grading—a 2016 consensus group statement of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 36:1097–103
     [Google Scholar]
  21. 21. 
    Cantu E, Suzuki Y, Diamond JM et al. 2016. Protein quantitative trait loci analysis identifies genetic variation in the innate immune regulator TOLLIP in post-lung transplant primary graft dysfunction risk. Am. J. Transplant. 16:833–40
     [Google Scholar]
  22. 22. 
    Shaver CM, Wickersham N, McNeil JB et al. 2018. Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight 3:e98546
     [Google Scholar]
  23. 23. 
    Diamond JM, Ramphal K, Porteous MK et al. 2018. Association of long pentraxin-3 with pulmonary hypertension and primary graft dysfunction in lung transplant recipients. J. Heart Lung Transplant. 37:792–94
     [Google Scholar]
  24. 24. 
    Cantu E, Shah RJ, Lin W et al. 2015. Oxidant stress regulatory genetic variation in recipients and donors contributes to risk of primary graft dysfunction after lung transplantation. J. Thorac. Cardiovasc. Surg. 149:596–602.e3
     [Google Scholar]
  25. 25. 
    Diamond JM, Meyer NJ, Feng R et al. 2012. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am. J. Respir. Crit. Care Med. 186:546–52
     [Google Scholar]
  26. 26. 
    Khalifah AP, Hachem RR, Chakinala MM et al. 2005. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am. J. Transplant. 5:2022–30
     [Google Scholar]
  27. 27. 
    Levine DJ, Glanville AR, Aboyoun C et al. 2016. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 35:397–406
     [Google Scholar]
  28. 28. 
    Mangi AA, Mason DP, Nowicki ER et al. 2011. Predictors of acute rejection after lung transplantation. Ann. Thorac. Surg. 91:1754–62
     [Google Scholar]
  29. 29. 
    Palmer SM, Klimecki W, Yu L et al. 2007. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am. J. Transplant. 7:693–99
     [Google Scholar]
  30. 30. 
    Calabrese F, Lunardi F, Nannini N et al. 2015. Higher risk of acute cellular rejection in lung transplant recipients with cystic fibrosis. Ann. Transplant. 20:769–76
     [Google Scholar]
  31. 31. 
    Todd JL, Neely ML, Kopetskie H et al. 2020. Risk factors for acute rejection in the first year after lung transplant: a multicenter study. Am. J. Respir. Crit. Care Med. 202:4576–85
     [Google Scholar]
  32. 32. 
    Roux A, Mourin G, Fastenackels S et al. 2013. CMV driven CD8+ T-cell activation is associated with acute rejection in lung transplantation. Clin. Immunol. 148:16–26
     [Google Scholar]
  33. 33. 
    Paraskeva M, Bailey M, Levvey BJ et al. 2011. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am. J. Transplant 11:2190–96
     [Google Scholar]
  34. 34. 
    Lewandowska DW, Schreiber PW, Schuurmans MM et al. 2017. Metagenomic sequencing complements routine diagnostics in identifying viral pathogens in lung transplant recipients with unknown etiology of respiratory infection. PLOS ONE 12:e0177340
     [Google Scholar]
  35. 35. 
    Palmer SM, Miralles AP, Lawrence CM et al. 1999. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 116:127–33
     [Google Scholar]
  36. 36. 
    Snell GI, Westall GP, Levvey BJ et al. 2014. A randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation. Am. J. Transplant. 14:1191–98
     [Google Scholar]
  37. 37. 
    Hachem RR, Yusen RD, Chakinala MM et al. 2007. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J. Heart Lung Transplant. 26:1012–18
     [Google Scholar]
  38. 38. 
    Treede H, Glanville AR, Klepetko W et al. 2012. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J. Heart Lung Transplant. 31:797–804
     [Google Scholar]
  39. 39. 
    Chakinala MM, Ritter J, Gage BF et al. 2005. Reliability for grading acute rejection and airway inflammation after lung transplantation. J. Heart Lung Transplant. 24:652–57
     [Google Scholar]
  40. 40. 
    De Vlaminck I, Martin L, Kertesz M et al. 2015. Noninvasive monitoring of infection and rejection after lung transplantation. PNAS 112:13336–41
     [Google Scholar]
  41. 41. 
    Greenland JR, Jewell NP, Gottschall M et al. 2014. Bronchoalveolar lavage cell immunophenotyping facilitates diagnosis of lung allograft rejection. Am. J. Transplant. 14:831–40
     [Google Scholar]
  42. 42. 
    Speck NE, Schuurmans MM, Benden C et al. 2017. Plasma and bronchoalveolar lavage samples in acute lung allograft rejection: the potential role of cytokines as diagnostic markers. Respir. Res. 18:151
     [Google Scholar]
  43. 43. 
    Aguilar PR, Carpenter D, Ritter J et al. 2018. The role of C4d deposition in the diagnosis of antibody-mediated rejection after lung transplantation. Am. J. Transplant. 18:936–44
     [Google Scholar]
  44. 44. 
    Witt CA, Gaut JP, Yusen RD et al. 2013. Acute antibody-mediated rejection after lung transplantation. J. Heart Lung Transplant. 32:1034–40
     [Google Scholar]
  45. 45. 
    Ensor CR, Yousem SA, Marrari M et al. 2017. Proteasome inhibitor carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings. Am. J. Transplant. 17:1380–88
     [Google Scholar]
  46. 46. 
    Vermuelen KM, van der Bij W, Erasmus ME, TenVergert EM 2007. Long-term health-related quality of life after lung transplantation: different predictors for different dimensions. J. Heart Lung Transplant. 26:188–93
     [Google Scholar]
  47. 47. 
    Davis RD Jr, Lau CL, Eubanks S et al. 2003. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J. Thorac. Cardiovasc. Surg. 125:533–42
     [Google Scholar]
  48. 48. 
    Snyder LD, Finlen-Copeland CA, Turbyfill WJ et al. 2010. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am. J. Respir. Crit. Care Med. 181:1391–96
     [Google Scholar]
  49. 49. 
    Glanville AR, Verleden GM, Todd JL et al. 2019. Chronic lung allograft dysfunction: definition and update of restrictive allograft syndrome—a consensus report from the Pulmonary Council of the ISHLT. J. Heart Lung Transplant. 38:483–92
     [Google Scholar]
  50. 50. 
    Verleden GM, Glanville AR, Lease ED et al. 2019. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment—a consensus report from the Pulmonary Council of the ISHLT. J. Heart Lung Transplant. 38:493–503
     [Google Scholar]
  51. 51. 
    Todd JL, Jain R, Pavlisko EN et al. 2014. Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction. Am. J. Respir. Crit. Care Med. 189:159–66
     [Google Scholar]
  52. 52. 
    DerHovanessian A, Todd JL, Zhang A et al. 2016. Validation and refinement of chronic lung allograft dysfunction phenotypes in bilateral and single lung recipients. Ann. Am. Thorac. Soc. 13:627–35
     [Google Scholar]
  53. 53. 
    Vanaudenaerde BM, De Vleeschauwer SI, Vos R et al. 2008. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am. J. Transplant. 8:1911–20
     [Google Scholar]
  54. 54. 
    Fan L, Benson HL, Vittal R et al. 2011. Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation. Am. J. Transplant. 11:911–22
     [Google Scholar]
  55. 55. 
    Burlingham WJ, Love RB, Jankowska-Gan E et al. 2007. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J. Clin. Investig. 117:3498–506
     [Google Scholar]
  56. 56. 
    Chiu S, Fernandez R, Subramanian V et al. 2016. Lung injury combined with loss of regulatory T cells leads to de novo lung-restricted autoimmunity. J. Immunol. 197:51–57
     [Google Scholar]
  57. 57. 
    Goers TA, Ramachandran S, Aloush A et al. 2008. De novo production of K-α1 tubulin-specific antibodies: role in chronic lung allograft rejection. J. Immunol. 180:4487–94
     [Google Scholar]
  58. 58. 
    Palmer SM, Burch LH, Trindade AJ et al. 2005. Innate immunity influences long-term outcomes after human lung transplant. Am. J. Respir. Crit. Care Med. 171:780–85
     [Google Scholar]
  59. 59. 
    Todd JL, Wang X, Sugimoto S et al. 2014. Hyaluronan contributes to bronchiolitis obliterans syndrome and stimulates lung allograft rejection through activation of innate immunity. Am. J. Respir. Crit. Care Med. 189:556–66
     [Google Scholar]
  60. 60. 
    Todd JL, Kelly FL, Nagler A et al. 2020. Amphiregulin contributes to airway remodeling in chronic allograft dysfunction after lung transplantation. Am. J. Transplant. 20:825–33
     [Google Scholar]
  61. 61. 
    Weigt SS, Wang X, Palchevskiy V et al. 2017. Gene expression profiling of bronchoalveolar lavage cells preceding a clinical diagnosis of chronic lung allograft dysfunction. PLOS ONE 12:e0169894
     [Google Scholar]
  62. 62. 
    Corris PA, Ryan VA, Small T et al. 2015. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax 70:442–50
     [Google Scholar]
  63. 63. 
    Vos R, Vanaudenaerde BM, Verleden SE et al. 2011. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur. J. Respir. 37:164–72
     [Google Scholar]
  64. 64. 
    Ruttens D, Verleden SE, Vandermeulen E et al. 2016. Prophylactic azithromycin therapy after lung transplantation: post hoc analysis of a randomized controlled trial. Am. J. Transplant. 16:254–61
     [Google Scholar]
  65. 65. 
    Verleden GM, Verleden SE, Vos R et al. 2011. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transplant Int 24:651–56
     [Google Scholar]
  66. 66. 
    Ruttens D, Verleden SE, Demeyer H et al. 2018. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a randomized controlled trial. PLOS ONE 13:e0193564
     [Google Scholar]
  67. 67. 
    Benden C, Haughton M, Leonard S, Huber LC 2017. Therapy options for chronic lung allograft dysfunction—bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: a systematic review. J. Heart Lung Transplant. 36:921–33
     [Google Scholar]
  68. 68. 
    Ensor CR, Rihtarchik LC, Morrell MR et al. 2017. Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation. Clin. Transplant. 31:e12899
     [Google Scholar]
  69. 69. 
    Kawut SM, Lederer DJ, Keshavjee S et al. 2008. Outcomes after lung retransplantation in the modern era. Am. J. Respir. Crit. Care Med. 177:114–20
     [Google Scholar]
/content/journals/10.1146/annurev-med-080119-103200
Loading
Advances in Human Lung Transplantation
Annual Review of Medicine 72, 135 (2021); https://doi.org/10.1146/annurev-med-080119-103200
/content/journals/10.1146/annurev-med-080119-103200
/content/journals/10.1146/annurev-med-080119-103200
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error